| Apremilast has demonstrated a favorable benefit–risk profile in 706,585 unique patients (557,379 patient-years) worldwide. |
| This analysis further demonstrates that apremilast is a safe, oral treatment option for long-term use up to 5 years in patients with psoriasis, psoriatic arthritis, or Behçet’s syndrome. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.